Business Description
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US98422E1038
Share Class Description:
STU:2B30: Ordinary SharesDescription
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | -0.09 | |||||
| Debt-to-Equity | -9.57 | |||||
| Debt-to-EBITDA | -11.75 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.58 | |||||
| Beneish M-Score | -3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.5 | |||||
| 3-Year EBITDA Growth Rate | 54.7 | |||||
| 3-Year EPS without NRI Growth Rate | 39.8 | |||||
| 3-Year FCF Growth Rate | 42.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.87 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.89 | |||||
| 9-Day RSI | 40.73 | |||||
| 14-Day RSI | 48.06 | |||||
| 3-1 Month Momentum % | 17.49 | |||||
| 6-1 Month Momentum % | 46.48 | |||||
| 12-1 Month Momentum % | 66.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.76 | |||||
| Days Inventory | 430.5 | |||||
| Days Sales Outstanding | 80.32 | |||||
| Days Payable | 91.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.3 | |||||
| Shareholder Yield % | -8.94 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.36 | |||||
| Operating Margin % | -24.11 | |||||
| Net Margin % | -33.69 | |||||
| FCF Margin % | -17.27 | |||||
| ROA % | -19.24 | |||||
| ROIC % | -20.1 | |||||
| 3-Year ROIIC % | 19.84 | |||||
| ROC (Joel Greenblatt) % | -83.07 | |||||
| ROCE % | -14.7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.53 | |||||
| EV-to-EBIT | -19.28 | |||||
| EV-to-EBITDA | -29.94 | |||||
| EV-to-Revenue | 3.69 | |||||
| EV-to-Forward-Revenue | 2.76 | |||||
| EV-to-FCF | -21.4 | |||||
| Price-to-GF-Value | 1.1 | |||||
| Earnings Yield (Greenblatt) % | -5.19 | |||||
| FCF Yield % | -6.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xeris Biopharma Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 171.64 | ||
| EPS (TTM) (€) | -0.404 | ||
| Beta | 0.46 | ||
| 3-Year Sharpe Ratio | 0.58 | ||
| 3-Year Sortino Ratio | 0.98 | ||
| Volatility % | 56.87 | ||
| 14-Day RSI | 48.06 | ||
| 14-Day ATR (€) | 0.094512 | ||
| 20-Day SMA (€) | 3.136 | ||
| 12-1 Month Momentum % | 66.07 | ||
| 52-Week Range (€) | 1.557 - 3.49 | ||
| Shares Outstanding (Mil) | 149.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xeris Biopharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xeris Biopharma Holdings Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xeris Biopharma Holdings Inc Frequently Asked Questions
What is Xeris Biopharma Holdings Inc(STU:2B30)'s stock price today?
The current price of STU:2B30 is €3.09. The 52 week high of STU:2B30 is €3.49 and 52 week low is €1.56.
When is next earnings date of Xeris Biopharma Holdings Inc(STU:2B30)?
The next earnings date of Xeris Biopharma Holdings Inc(STU:2B30) is 2025-03-06 Est..
Does Xeris Biopharma Holdings Inc(STU:2B30) pay dividends? If so, how much?
Xeris Biopharma Holdings Inc(STU:2B30) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers